NEW

INOFOLIC® HP *Line*

PATENT

Lo.Li. Pharma
INTERNATIONAL

≈70%

OF PCOS WOMEN POSITIVELY RESPOND TO INOSITOL

MYO MODULATES INSULIN ACTIVITY[1]



- ***CONTROL*** *LH/FSH*[2]
- ***REDUCTION*** *of androgens production*[3]
- ***IMPROVEMENT*** *of glucose metabolism*[4]
- ***REDUCTION*** *of insulin resistance*[5]

MYO-INOSITOL IS THE SECOND MESSENGER OF FSH



- ***INCREASE*** *of response to FSH*
- ***PROMOTION*** *of ovulation*

≈30%

OF PCOS WOMEN DO NOT RESPOND TO INOSITOL

Study	Patients	Treatments	EFFECT
Kamenov et al. *Gynecol Endocrinol. 2015*	**50 PCOS patients** w/ anovulation and IR	**Myo-Inositol** (2g twice/day) for 3 months	**38.3% resistants**
Raffone et al. *Gynecol Endocrinol. 2010*	**60 PCOS patients** w/ menstrual regularity	**Myo-Inositol** (2g twice/day) for 6 months	**28.3% resistants**
Gerli et al. *Eur Rev Med Pharmacol Sci. 2007*	**45 PCOS patients** w/ oligomenorrhea	**Myo-Inositol** (2g twice/day) for 14 months	**30% resistants**
Iuorno et al. *Endocr Pract. 2002*	**10PCOS patients** thins	**D-chiro-Inositol** (600 mg) for 6-8 months	**40% resistants**

INOSITOL-RESISTANCE

REDUCED **INOSITOLS** ABSORPTION

- ***INCREASE*** *of recovery time of menstrual regularity*
- ***REDUCED*** *glycemic control*
- ***LESS*** *compliance*

WHY?

IF 10,91

CellPress

Sex, Microbes, and Polycystic Ovary Syndrome

Varykina G. Thackray



IF 4,7

frontiers in Microbiology

Dysbiosis of Gut Microbiota Associated with Clinical Parameters in Polycystic Ovary Syndrome

Rui Liu, Chenhong Zhang, Yu Shi, Feng Zhang, Linxia Li, Xuejiao Wang, Yunxia Ling, Huaqing Fu, Weiping Dong, Jian Shen, Andrew Reeves, Andrew S. Greenberg, Liping Zhao, Yongde Peng and Xiaoying Ding





MALABSORPTION IN PCOS WOMEN INDUCES INOSITOL-RESISTANCE

PCOS women
with anovulation

3 MONTHS
of treatment with **MYO**

2 g twice/day

62% of women **ovulate**
MYO plasma levels: **38 µmol/l**

38% of women do not **ovulate**
MYO plasma levels: **17 µmol/l**

NON-RESPONDER WOMEN
have a ***LACKING ABSORPTION***
of ***MYO-INOSITOL[6]***

IS IT POSSIBLE TO MAXIMAZE THE CLINICAL EFFICACY OF INOSITOL TREATMENTS?

Yes, *thanks to the* ***ALPHA-LACTALBUMIN!***

MYO-INOSITOL ALONE

62% efficacy

NEW

MYO-INOSITOL + ALPHA-LACTALBUMIN

95% efficacy



Comparison between MI plasma levels (µmol/l) in 18 healthy volunteers after the administration of MI alone and plus alpha-lactalbumin

Significant increase of **MYO-INOSITOL** blood level[7]



DCI trans-epithelial passagge in CACO-2 cells in absence and in presence of of α-LA peptides and restroration of tight junctions to physiological conditions (yellow column)

Reversible modulation of **D-CHIRO INOSITOL** intestinal permeability

ALPHA-LACTALBUMIN *improves the absorption of* ***INOSITOLS*** *in a* ***REVERSIBLE AND PHYSIOLOGICAL*** *way*

INOFOLIC® LINE *High Performance*

PENDING PATENT PENDING

NEW

BMI < 25



SACHETS

Myo-Inositol
Alpha-Lactalbumin
Folic Acid

NEW

BMI ≥ a 25

SOFT-GEL TECHNOLOGY

MYO:DCI 40:1
Alpha-Lactalbumin
Folic Acid

- ***95% EFFICACY***
  of the therapy with MYO and DCI
- ***CONTROL***
  of metabolic parameters
- ***CONTROL***
  of hormonal parameters
- *Patient*
  SATISTACTION

INOFOLIC® becomes *High Performance*

INOFOLIC® HP

BMI < 25

1 sachet, twice a day

COMPOSITION 2 sachets		
Myo-inositol	4000 mg	-
Alpha-lactalbumin	100 mg	-
Folic Acid	400 mcg	200

INOFOLIC® Combi HP

PATENTS: N:0001408659 / N:0001404868

BMI ≥ 25

1 softgel cap, twice a day

COMPOSITION 2 caps		
Myo-inositol	1100 mg	-
Alpha-lactalbumin	28.2 mg	-
D-Chiro-inositolo	27.6 mg	-
Folic Acid	400 mcg	200

References: 1. Laganà AS., Trends Endocrinol Metab. 2018 Nov; 29(11):768-780 **2.** Unfer V. et al., Endocr Connect. 2017 Nov; 6(8):647-658 **3.** Costantino D. et al., Eur Rev Med Pharmacol Sci. 2009 Mar-Apr; 13(2):105-110 **4.** Nordio M. et al., Eur Rev Med Pharmacol Sci 2012; 16:575-581 **5.** Benelli E. et al., Int J Endocrinol. 2016; 2016:3204083 **6.** Montanino Oliva M., J Ovarian Res. 2018 May 10;11(1):38 **7.** Monastra G., Curr Drug Deliv. 2018;15(9):1305-1311 **8.** Monastra G., to be published.

Lo.Li. Pharma INTERNATIONAL

For exclusive use by physicians